F-1: Gelteq Limited Files F-1 for Resale of Up to 4 Million Shares by Lincoln Park Capital Amidst Ongoing Losses and Going Concern Doubt

Gelteq Limited has filed an F-1 registration statement for the resale of up to 4,000,000 ordinary shares by Lincoln Park Capital Fund, LLC, aiming to secure up to $12 million in gross proceeds to fund its R&D and operations amidst a history of significant operating losses and a going concern doubt.

Summary

• Gelteq Limited is a clinical and science-based company focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products.
• The company filed an F-1 registration statement for the resale of up to 4,000,000 ordinary shares by Lincoln Park Capital Fund, LLC.
• Gelteq may receive up to $12,000,000 in gross proceeds from the sale of its Ordinary Shares to Lincoln Park under a Purchase Agreement dated March 13, 2025, but will not receive proceeds from Lincoln Park's resale of shares.
• Gelteq completed its initial public offering (IPO) on October 30, 2024, raising $5.2 million in gross proceeds at a price of US$4.00 per share.
• The company has a history of significant operating losses, including AUD$3,546,195 for the fiscal year ended June 30, 2024, and AUD$3,304,359 for the six months ended December 31, 2024.
• Revenue from contracts with customers was nil for the six months ended December 31, 2024, and also nil for the fiscal year ended June 30, 2024.
• Auditors have raised substantial doubt about Gelteq's ability to continue as a going concern due to recurring losses and a current liability position.
• As of December 31, 2024, cash and cash equivalents increased to AUD$3,046,602 from AUD$24,522 at June 30, 2024, primarily due to IPO proceeds.
• The working capital deficit improved from AUD$(3,562,838) at June 30, 2024, to AUD$(1,339,525) at December 31, 2024.
• Gelteq's strategy involves out-licensing its technology and manufacturing existing white-label products across pet, sports, pharmaceutical, over-the-counter (OTC), and nutraceutical verticals.
• The company forecasts significant annual revenue growth: 259% for FY2026, 117% for FY2027, 86% for FY2028, and 38% for FY2029, with a long-term EBITDA margin of 29%.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including recurring losses and a going concern warning from auditors. While it has secured a significant equity line and completed an IPO, its revenue generation is currently nil, and future profitability is highly uncertain and dependent on successful market penetration and regulatory approvals. The strategic focus on R&D and new markets offers long-term potential but is currently capital-intensive and speculative.

Positives

• Secured a Purchase Agreement with Lincoln Park Capital Fund, LLC for up to $12,000,000 in gross proceeds, providing a potential source of capital for operations.
• Successfully completed an Initial Public Offering (IPO) on October 30, 2024, raising $5.2 million in gross proceeds.
• Cash and cash equivalents significantly increased to AUD$3,046,602 as of December 31, 2024, from AUD$24,522 at June 30, 2024, improving immediate liquidity.
• The working capital deficit improved from AUD$(3,562,838) at June 30, 2024, to AUD$(1,339,525) at December 31, 2024.
• Received FDA approval for a suitability petition for a new animal drug in December 2024, which could shorten the approval timeline by foregoing safety and effectiveness studies.
• Established a new rental contract for laboratory facilities with Monash University on February 2, 2024, to support further research and engagement with university staff and students.
• Entered into a sales and distribution agreement with WPIC Marketing and Technologies Limited on December 2, 2024, to assist with sales of SportsGel products in the Asia Pacific region, starting with China.
• Holds multiple patent families and applications, including a granted U.S. patent (10,983,132) for an oral glucose tolerance test gel, strengthening its intellectual property portfolio.
• Management believes initial pilot sales to existing customers will increase market exposure and potentially lead to higher-margin future orders.
• Shareholder loans were extended to December 31, 2025, alleviating immediate short-term liability pressure.

Negatives

• Reported significant and recurring operating losses: AUD$3,546,195 for FY2024, AUD$3,506,220 for FY2023, AUD$3,304,359 for the six months ended December 31, 2024, and AUD$1,685,644 for the six months ended December 31, 2023.
• There is substantial doubt about the company's ability to continue as a going concern, as highlighted by independent auditors in their reports for FY2023 and FY2024, and in the unaudited financial statements for the six months ended December 31, 2024.
• Revenue from contracts with customers was nil for the six months ended December 31, 2024, and also nil for the fiscal year ended June 30, 2024, indicating a lack of consistent sales generation.
• Current liabilities exceeded current assets by AUD$1,339,525 as of December 31, 2024.
• Experienced delays in fulfilling past orders due to certain customers' cash flow difficulties, impacting timely revenue recognition.
• The market for the company's gel products is new and rapidly evolving, with no assurance that the industry will develop as envisioned or that the company will achieve meaningful market share.
• The company has not been adequately staffed to reach projected forecasted revenues, requiring additional sales managers in the future.
• Corporate and administrative expenses significantly increased to AUD$3,301,299 for the six months ended December 31, 2024, from AUD$1,661,589 in the prior comparable period.
• Research expenses increased to AUD$314,472 for the six months ended December 31, 2024, from AUD$100,934 in the prior comparable period.
• Finance costs increased to AUD$620,785 for the six months ended December 31, 2024, from AUD$286,791 in the prior comparable period.
• The sale of Ordinary Shares to Lincoln Park will have a dilutive impact on existing shareholders.
• The Purchase Agreement with Lincoln Park includes limitations, such as the 19.99% Exchange Cap, which may restrict the company's ability to fully utilize the $12 million commitment without further shareholder approval or a higher average share price.
• An inventory write-off of AUD$95,201 occurred in FY2024 due to expired shelf life.

Risks

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• Substantial additional financing will be required to achieve the company's goals; a failure to obtain necessary capital could force delays, reductions, or termination of product development or commercialization efforts.
• The market for the company's gel products is new and rapidly evolving, and there is no assurance that it will develop as envisioned or that the company will succeed in acquiring meaningful market share.
• Operating results may fluctuate significantly due to factors like raw material costs, manufacturing expenses, and marketing/distribution costs, making future performance difficult to predict.
• Fluctuations in raw material prices and supply chain disruptions (e.g., due to geopolitical conflicts like the Russia-Ukraine and Israel-Hamas conflicts, or cross-border tariffs) could increase product costs and adversely affect operations.
• Customers have a history of delaying orders due to cash flow difficulties, which has limited the company's ability to generate expected revenue in a timely manner.
• There is substantial doubt about the company's ability to continue as a going concern, as indicated by recurring losses and a current liability position.
• The company's success is highly dependent on market acceptance of its technology and products; inability to obtain customer acceptance or effectively market products will materially impair the business.
• The loss of services of key personnel, particularly Chief Executive Officer Nathan J. Givoni, would negatively affect the business.
• An active, liquid trading market for the company's Ordinary Shares may not be sustained, leading to potential difficulty in selling shares or depressing the market price.
• Future sales of a substantial number of Ordinary Shares by existing shareholders, including the selling shareholder Lincoln Park, could cause the stock price to decline due to dilution or market perception.
• Management has broad discretion over the use of proceeds from the sale of Purchase Shares to Lincoln Park, which may not align with shareholders' expectations.
• The terms of the Purchase Agreement limit the amount of Ordinary Shares that can be issued to Lincoln Park (Exchange Cap), potentially limiting the company's ability to fully utilize the arrangement to enhance cash resources without shareholder approval.
• Failure to develop or maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements or comply with regulations, potentially leading to Nasdaq delisting.
• Products in the pharmaceutical vertical will require regulatory approval, and clinical trials can be longer and more costly than expected, with negative outcomes or additional data requirements causing delays and increased R&D costs.
• The company faces significant competition in the highly regulated drug delivery market from companies with substantially greater financial, technical, and human resources.
• Inability to protect intellectual property rights could adversely affect the business, competitive position, financial condition, and results of operations.
• Expanding operations internationally exposes the company to additional tax, compliance, market, and other risks.
• The company may be adversely affected by foreign currency fluctuations.
• Any failure to comply with anticorruption and anti-money laundering laws could subject the company to penalties and other adverse consequences.
• Failure to comply with U.S. and international import and export laws could adversely impact the business.
• Any failure to comply with laws relating to labor and employment could subject the company to penalties and other adverse consequences.

Future Outlook

Gelteq expects to continue incurring operating losses for the foreseeable future but is prioritizing sales activities across animal health, nutraceutical, sports, over-the-counter, and pharmaceuticals verticals. The company is focusing on pharmaceutical research, particularly its 505(b)(2) application, and plans to expand its product suite. Significant revenue growth is forecasted, with 259% for FY2026, 117% for FY2027, 86% for FY2028, and 38% for FY2029, aiming for a long-term EBITDA margin of 29%. The company intends to onboard additional sales managers in FY2026 and expects new online stores in China to contribute to revenue.

Management Comments

• "We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products."
• "We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (white label)."
• "We believe this will have a short-term impact on sales revenue which was nil for the six months ended December 31, 2023."
• "With the Monash Facilities established and fitted, as well as the closing of our IPO, we are prioritizing our sales activities with a focus on the animal health, nutraceutical, sports, over-the-counter and pharmaceuticals verticals."
• "We continue to discuss revenue opportunities with existing and prospective customers and we remain confident in our sales strategy and our strong existing new business pipeline, and we would fulfil our revenue numbers should each existing potential client in the pipeline eventuate."
• "We have put in place more rigorous qualification procedures to ensure customers have the financial ability to pay for its orders."
• "We do not expect to require additional capital apart from the proceeds of this offering should our operations continue as forecasted."
• "Should we experience lower than expected sales volumes or lower growth opportunities, then we may be required to consider additional financing options to continue the Company’s growth to achieve positive cash flow."
• "However, we intend to adjust our expenses to align with the revenue generated to ensure we remain financially solvent."
• "Our vision is to change the way good health is delivered to both humans and animals through our patent pending multiple-health-ingredient gel dosage forms."

Industry Context

Gelteq operates in the competitive and highly regulated drug delivery market, specifically targeting the oral drug delivery segment with its innovative gel-based technology. The company aims to carve out a niche in 'blue ocean markets' within the pharmaceutical, OTC, nutraceutical, and pet care sectors, where it believes current oral delivery methods (pills, tablets, gummies) are inadequate. The broader oral drug delivery market is substantial, projected to grow from approximately USD$769 billion to USD$1,227 billion by 2027. The nutraceuticals market is also experiencing significant growth, expected to reach USD$270 billion by 2028, driven by consumer demand for health-enhancing products. The trend of 'pet humanization' is fueling growth in the pet health and supplement industry, with pet supplements showing a 116% growth from 2019 to 2020 in North America. Gelteq's technology addresses common issues like dysphagia (difficulty swallowing), taste masking, and precise dosage, which are critical unmet needs across these markets. The company also sees potential in 'Patent Life Cycle management' for existing drugs by offering new, patentable gel-based dosage forms.

Comparison to Industry Standards

• Gelteq's forecast gross margins, increasing from 52% in CY25 to 58% in CY29, are stated to be in line with comparable industry gross margins.
• The company's long-term forecast EBITDA margin of 29% is considered comparable to that of comparable industries in relevant world markets, despite negative EBITDA in early years typical for startups.
• Gelteq positions its gel delivery system as unique within the pharmaceutical space, stating it is not aware of any companies currently offering drug delivery in a similar gel base, aiming to be superior to traditional oral delivery methods like pills and gummies.
• The company acknowledges that competitors in the pharmaceutical market, such as Oramed Pharmaceuticals, IntelGenx Technologies Corp., BioDelivery Sciences International Inc., Lexaria Bioscience Corp., Taro Pharmaceuticals Industries Ltd., Catalent Inc., Insulet Corporation, Nutriband Inc., Virpax Pharmaceuticals Inc., and Hempfusion Wellness Inc., possess substantially greater financial, technical, and human resources.
• Gelteq maintains a research partnership with Monash University, which is ranked among the top universities globally in pharmaceutical science, leveraging its expertise for technology validation and development.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation the outcome of which, if determined adversely, would individually or in the aggregate be reasonably expected to have a material adverse effect on the business, operating results, cash flows, or financial condition.

Related Party Transactions

• Shareholder Loans: Unsecured loans from B&M Givoni Pty Ltd ATF B&M Givoni Superannuation Fund (associated with CEO Nathan J. Givoni's parents) and Jeffrey W. Olyniec (director) totaling AUD$1,493,445 (initially), with a 12% annual interest rate. These loans have been extended multiple times, with the latest maturity date of December 31, 2025. AUD$772,136 (approximately USD$501,888) was paid to redeem some loans in March 2025.
• Loans from Associated Entities: Unsecured loans from Nutrition DNA and Domalina Unit Trust (entities associated with directors Nathan Givoni and Simon Szewach) with a 5-year maturity and 0.5% annual interest. The outstanding balance was AUD$156,434 as of December 31, 2024.
• Convertible Notes from Related Parties: Convertible notes received from entities related to Nathan Givoni and Jeffrey Olyniec, with an outstanding balance of AUD$1,088,208 as of December 31, 2024.
• Consulting Services: Paid Asiana Trading Corporation Limited (an entity associated with Jeffrey W. Olyniec until December 2021) AUD$261,916 (USD$175,000) for management and legal services in China for the six months ended December 31, 2024.
• Office Space Rental: Entered into a lease agreement with Lifestyle Breakthrough Holdings U/T (an entity associated with Nathan J. Givoni and Simon H. Szewach) for office space. The lease expired on November 1, 2023, and continued on a month-to-month basis, with expected termination by the end of the fiscal year ending June 30, 2025.
• The company notes that transactions with related parties have not undergone a formal benchmarking process to establish whether arrangements are conducted under normal market terms and conditions, and therefore, such transactions may not be considered at arm's length.

Stakeholder Impact

• Shareholders: Face potential significant dilution from future share sales to Lincoln Park and other capital raises. There is a high risk of loss of investment due to recurring substantial losses and the explicit going concern doubt. The share price is expected to remain volatile.
• Employees: Impacted by changes in key management roles (CFO, CSO, Executive Chairman). The company plans to implement an equity incentive plan and performance-based incentives to attract and retain qualified personnel.
• Customers: May experience delays in order fulfillment due to past operational issues and customer cash flow problems. The company has implemented more rigorous qualification procedures for future customers.
• Creditors: The substantial doubt about the company's ability to continue as a going concern raises concerns regarding the repayment of debts. Shareholder loans and convertible notes have required multiple extensions, indicating ongoing financial strain.

Next Steps

• Register for resale under the Securities Act any additional Ordinary Shares beyond the 4,000,000 currently registered, if the company elects to sell more to Lincoln Park to reach the $12 million commitment.
• Continue research and development, particularly in the pharmaceutical/OTC vertical.
• Prioritize pharmaceutical research on the existing 505(b)(2) application and seek other potential pharmaceutical candidates.
• Conduct formal studies for canine products in the fiscal year ending June 30, 2026.
• Commence initial clinical trials for an animal-based medication early in the fiscal year ending June 30, 2026.
• Design two clinical trials (animal and human) to showcase bioequivalence and safety for the off-patent API product entering the 505(b)(2) pathway.
• Run shelf-life stability testing concurrently with clinical trials at an FDA registered and inspected facility.
• Onboard an additional three sales managers in the fiscal year ending June 30, 2026, once adequate funds have been raised.
• Launch the SportsGel brand in the Asia Pacific region, commencing with China in March 2025.
• Continue discussions with existing and prospective customers to fulfill revenue targets and leverage pilot orders for increased market exposure and higher-margin future sales.
• Adjust expenses to align with revenue generated if lower than expected sales volumes or growth opportunities occur to ensure financial solvency.
• Potentially require further extensions for shareholder loans for the fiscal year ending June 30, 2025, if determined to be needed.
• The board expects to approve a non-employee director compensation policy in the fiscal year ending June 30, 2026.

Key Dates

Recommendation

Keywords

Gelteq Limited, SEC F-1 filing, Lincoln Park Capital, Ordinary Shares, Resale, Capital Raise, Pharmaceutical, Nutraceuticals, Pet Care, Gel-based Delivery, White Label, IPO, Operating Losses, Going Concern, Risk Factors, Corporate Governance, Intellectual Property, Clinical Trials, FDA Approval, Nasdaq, GELS, Australia, Research and Development, Financial Statements, Convertible Notes, Dilution, Market Acceptance, Supply Chain, Geopolitical Risk, Dysphagia, Taste Masking